Rimonabant reduces obesity‐associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats

This study investigated the effects of rimonabant (SR141716), an antagonist of the cannabinoid receptor type 1 (CB1), on obesity‐associated hepatic steatosis and related features of metabolic syndrome: inflammation (elevated plasma levels of tumor necrosis factor alpha [TNFα]), dyslipidemia, and reduced plasma levels of adiponectin. We report that oral treatment of obese (fa/fa) rats with rimonabant (30 mg/kg) daily for 8 weeks abolished hepatic steatosis. This treatment reduced hepatomegaly, reduced elevation of plasma levels of enzyme markers of hepatic damage (alanine aminotransferase, gamma glutamyltransferase, and alkaline phosphatase) and decreased the high level of local hepatic TNFα currently associated with steatohepatitis. In parallel, treatment of obese (fa/fa) rats with rimonabant reduced the high plasma level of the proinflammatory cytokine TNFα and increased the reduced plasma level of the anti‐inflammatory hormone adiponectin. Finally, rimonabant treatment also improved dyslipidemia by both decreasing plasma levels of triglycerides, free fatty acids, and total cholesterol and increasing the HDLc/LDLc ratio. All the effects of rimonabant found in this study were not or only slightly observed in pair‐fed obese animals, highlighting the additional beneficial effects of treatment with rimonabant compared to diet. These results demonstrate that rimonabant plays a hepatoprotective role and suggest that this CB1 receptor antagonist potentially has clinical applications in the treatment of obesity‐associated liver diseases and related features of metabolic syndrome. (HEPATOLOGY 2007.)

[1]  Y. Aggoun,et al.  Obesity, Metabolic Syndrome, and Cardiovascular Disease , 2007, Pediatric Research.

[2]  C. Mantzoros,et al.  Adiponectin and cancer: a systematic review , 2006, British Journal of Cancer.

[3]  F Xavier Pi-Sunyer,et al.  Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. , 2006, JAMA.

[4]  B. Scatton,et al.  The Cannabinoid CB1 Receptor Antagonist Rimonabant (SR141716) Inhibits Cell Proliferation and Increases Markers of Adipocyte Maturation in Cultured Mouse 3T3 F442A Preadipocytes , 2006, Molecular Pharmacology.

[5]  Y. Matsuzawa.  White adipose tissue and cardiovascular disease. , 2005, Best practice & research. Clinical endocrinology & metabolism.

[6]  C. Lavie,et al.  Importance and Management of Dyslipidemia in the Metabolic Syndrome , 2005, The American journal of the medical sciences.

[7]  J. Després,et al.  Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. , 2005, The New England journal of medicine.

[8]  T. Hibi,et al.  Tumour necrosis factor α signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice , 2005, Gut.

[9]  S. Jee,et al.  Obesity, Insulin Resistance and Cancer Risk , 2005, Yonsei medical journal.

[10]  F. Poordad,et al.  Nonalcoholic fatty liver disease: a review , 2005, Expert opinion on emerging drugs.

[11]  U. Pagotto,et al.  The endocannabinoid system and the treatment of obesity , 2005, Annals of medicine.

[12]  K. Mackie,et al.  Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. , 2005, The Journal of clinical investigation.

[13]  T. Kadowaki,et al.  Adiponectin and adiponectin receptors. , 2005, Endocrine reviews.

[14]  Y. Sharabi,et al.  Adiponectin: linking the metabolic syndrome to its cardiovascular consequences , 2005, Expert review of cardiovascular therapy.

[15]  A. Rissanen,et al.  Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study , 2005, The Lancet.

[16]  N. Chavez-Tapia,et al.  Adiponectin as a protective factor in hepatic steatosis. , 2005, World journal of gastroenterology.

[17]  R. Pratley,et al.  The evolving role of inflammation in obesity and the metabolic syndrome , 2005, Current diabetes reports.

[18]  A. Diehl,et al.  Cytokines and the pathogenesis of non-alcoholic steatohepatitis , 2005, Gut.

[19]  J. Herbert,et al.  The anti‐obesity effect of rimonabant is associated with an improved serum lipid profile , 2005, Diabetes, obesity & metabolism.

[20]  S. Kihara,et al.  Adiponectin as a biomarker of the metabolic syndrome. , 2004, Circulation journal : official journal of the Japanese Circulation Society.

[21]  I. S. Wood,et al.  Adipokines: inflammation and the pleiotropic role of white adipose tissue , 2004, British Journal of Nutrition.

[22]  Cynthia J. Girman,et al.  Plasma adiponectin levels and risk of myocardial infarction in men. , 2004, JAMA.

[23]  J. Romijn,et al.  Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[24]  K. Mak,et al.  Model of nonalcoholic steatohepatitis. , 2004, The American journal of clinical nutrition.

[25]  S. Borst.  The role of TNF-α in insulin resistance , 2004 .

[26]  G. Marchesini,et al.  Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship? , 2004, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[27]  G. Sonnenberg,et al.  A novel pathway to the manifestations of metabolic syndrome. , 2004, Obesity research.

[28]  L. Tartaglia,et al.  Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. , 2003, The Journal of clinical investigation.

[29]  Cranford L Scott,et al.  Diagnosis, prevention, and intervention for the metabolic syndrome. , 2003, The American journal of cardiology.

[30]  Yu Wang,et al.  The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. , 2003, The Journal of clinical investigation.

[31]  P. Soubrié,et al.  The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. , 2003, Molecular pharmacology.

[32]  P. Soubrié,et al.  Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. , 2003, American journal of physiology. Regulatory, integrative and comparative physiology.

[33]  S. Kihara,et al.  Adiponectin Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice , 2002, Circulation.

[34]  S. Maruoka,et al.  Decreased plasma adiponectin concentrations in women with dyslipidemia. , 2002, The Journal of clinical endocrinology and metabolism.

[35]  J. Beattie,et al.  Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ , 2001, Proceedings of the Nutrition Society.

[36]  R. Palmiter,et al.  Leptin-regulated endocannabinoids are involved in maintaining food intake , 2001, Nature.

[37]  H. Tilg,et al.  Cytokines in alcoholic and nonalcoholic steatohepatitis. , 2000, The New England journal of medicine.

[38]  P. Carpino.  Patent focus on new anti-obesity agents: September 1999 - February 2000 , 2000 .

[39]  G. Gessa,et al.  Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. , 1998, Life sciences.

[40]  P. Soubrié,et al.  Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats , 1998, Psychopharmacology.

[41]  P. Soubrié,et al.  Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors , 1997, Psychopharmacology.

[42]  B. Spiegelman,et al.  Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. , 1995, The Journal of clinical investigation.

[43]  A. Mallat,et al.  Endocannabinoids as novel mediators of liver diseases. , 2006, Journal of endocrinological investigation.

[44]  L. Sechi,et al.  Plasma adiponectin is decreased in nonalcoholic fatty liver disease. , 2005, European journal of endocrinology.

[45]  Manoj Kumar.  STONE DISEASE _______________________________________________________________ Obesity, weight gain, and the risk of kidney stones , 2005 .

[46]  A. Aljada,et al.  Inflammation: the link between insulin resistance, obesity and diabetes. , 2004, Trends in immunology.

[47]  M. Haluzík,et al.  Adiponectin and its role in the obesity-induced insulin resistance and related complications. , 2004, Physiological research.

[48]  S. Borst.  The role of TNF-alpha in insulin resistance. , 2004, Endocrine.

[49]  B. Goldstein,et al.  Adiponectin: A novel adipokine linking adipocytes and vascular function. , 2004, The Journal of clinical endocrinology and metabolism.